Neuropsychiatric Signals With Vanzacaftor-Tezacaftor-Deutivacaftor: Early but Important Real-World Alert
A P Sawant, N Shaw, I J Clifton, H Saumtally, D G Peckham
Summary: A UK regional adult CF centre reports four cases (4.6%) of new or worsening neuropsychiatric symptoms among 84 patients started on standard-dose vanzacaftor-tezacaftor-deutivacaftor (VTD), the newest triple-combination CFTR modulator. Three of the four cases involved suicidal ideation and ultimately required switching back to elexacaftor-tezacaftor-ivacaftor (ETI), with rapid symptom resolution. Separately, three patients with pre-existing mental health conditions were proactively started on a reduced dose, with two of three achieving meaningful sweat chloride reduction and no adverse psychiatric events.
Why it matters: Neuropsychiatric adverse effects with ETI prompted post-marketing warnings, and this report confirms that VTD carries a similar — and possibly more severe in character — signal, now formally acknowledged by regulators. As VTD enters broader clinical use, particularly among patients switching from ETI, clinicians need a concrete framework for pre-treatment psychiatric assessment, monitoring protocols, and dose-adjustment strategies. The proactive reduced-dose approach in high-risk patients is a pragmatic contribution that deserves prospective evaluation. The fact that all four cases were reported to the UK MHRA Yellow Card scheme is appropriate and supports ongoing pharmacovigilance.
Expert perspective: This is a case series of four events at a single centre — inherently limited in sample size, generalizability, and the ability to distinguish drug-attributable causation from coincidence or natural fluctuation in mental health. The authors are appropriately candid about the most important methodological weakness: case ascertainment was purely clinical rather than through systematic structured psychiatric screening. This virtually guarantees underdetection; the true rate at this centre could be higher, and at centres without a proactive safety culture, it could be substantially underreported. The 4.6% crude rate is superficially comparable to published ETI real-world rates (~7–7.9%), but direct comparison is premature given different denominators, different follow-up durations, different baseline psychiatric burden across cohorts, and — critically — different severity profiles. The authors' observation that suicidal ideation appeared more frequent with VTD than in prior ETI series is clinically important but statistically uninterpretable from four cases.
The reduced-dose strategy in the three high-risk patients is biologically plausible and pharmacologically interesting, particularly given that deutivacaftor's modified pharmacokinetics theoretically affect CNS exposure. However, two of three achieving sweat chloride below 40 mmol/L is encouraging but cannot be taken as proof of therapeutic equivalence or safety — a controlled assessment with systematic outcomes measurement would be needed. Importantly, the mechanism linking CFTR modulation to neuropsychiatric effects remains poorly understood, and it is not yet clear whether the effect is class-specific, molecule-specific, or depends on individual CNS CFTR expression or vulnerability.
From a pharmacovigilance standpoint, this report performs a genuine service: it documents real-world signal with sufficient clinical detail to be actionable, it models transparent adverse-event reporting to a national regulator, and it raises the specific question of whether patients with pre-existing psychiatric conditions require a dose-modified initiation protocol. What is now needed is a prospective, multi-centre surveillance study with validated psychiatric instruments administered at standardized intervals after VTD initiation — ideally embedded within existing national CF registries — so that incidence, severity, risk factors, and dose-response relationships can be characterized with the rigor the question deserves.
Relevance: Cystic Fibrosis
Source: https://pubmed.ncbi.nlm.nih.gov/42763277/
---